Pharma Tech

ProBio signs global antibody licensing deal with AbTis

Nov 11, 2026, 10:42 AM

Read Full Article → ProBio signs global antibody licensing deal with AbTis

Translate article text

Choose a language and wait for the translated text.

ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.